Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12414686 | 1.00 | KMT2A (0.62) | KMT2AMAPK1GRM5HSD11B1MAPT | |
| SCHEMBL20306360 | 0.84 | SMN1; SMN2 (0.44) | KMT2AMAPK1HSD11B1MAPTHSD17B2 | |
| SCHEMBL6828707 | 0.81 | KMT2A (0.51) | KMT2AMAPK1GRM5MAPTP2RX7 | |
| SCHEMBL10013279 | 0.80 | KMT2A (0.58) | KMT2AMAPK1GRM5HSD11B1HSD17B2 | |
| SCHEMBL523337 | 0.79 | KMT2A (0.51) | KMT2AMAPK1GRM5HSD11B1MAPT | |
| SCHEMBL9939512 | 0.77 | KMT2A (0.66) | KMT2AMAPK1GRM5HSD11B1HSD17B2 | |
| SCHEMBL14302495 | 0.77 | KMT2A (0.66) | KMT2AMAPK1GRM5HSD11B1HSD17B2 | |
| SCHEMBL13979931 | 0.77 | KMT2A (0.66) | KMT2AMAPK1GRM5HSD11B1HSD17B2 | |
| SCHEMBL9938489 | 0.77 | KMT2A (0.66) | KMT2AMAPK1GRM5HSD11B1HSD17B2 | |
| SCHEMBL13752130 | 0.77 | KMT2A (0.58) | KMT2AMAPK1GRM5HSD11B1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1757598-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | AQP1, GLUL, GATD3 | KMT2A 1856/4885MAPK1 1570/4885GRM5 900/4885 |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | QPCT, GMPS, QPCTL | KMT2A 2369/4885MAPK1 1390/4885GRM5 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.